公开(公告)号：US20250051400A1

公开(公告)日：2025-02-13

申请号：US18822867

申请日：2024-09-03

Applicant: Repligen Corporation

Inventor： Paul Knick ,  Erik Fiedler ,  Ulrich Haupts ,  Maren Meysing

IPC: C07K14/31 ,  C07K1/22 ,  C07K16/06 ,  C07K17/00

Abstract: The present invention relates to Fc binding proteins comprising one or more Fc binding domains wherein at least one domain comprises of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-6 or 21. The invention further relates to affinity matrices comprising the Fc binding proteins of the invention. The invention also relates to a use of these Fc binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Fc binding proteins of the invention.

公开(公告)号：US20250034637A1

公开(公告)日：2025-01-30

申请号：US18798279

申请日：2024-08-08

Applicant: Roche Sequencing Solutions, Inc.

Inventor： Mark Ambroso ,  Timothy Craig ,  Matthew DiPietro ,  Corissa Harris ,  Marshall Porter

IPC: C12Q1/6869 ,  A61K38/02 ,  C07K14/00 ,  C07K14/31 ,  C12N15/01

Abstract: Described herein are variants of alpha-hemolysin having at least one amino acid substitution at H35G, E111N, M113A, and/or K147N in the mature, wild-type alpha-hemolysin amino acid sequence. In certain examples, the variant may have a substitution at E111S, M113S, T145S, K147S, or L135I in the mature alpha-hemolysin amino acid sequence. The α-hemolysin variants may also include a substitution at H144A and/or a series of glycine residues spanning residues 127 to 131 of the mature, wild-type alpha hemolysin. Also provided are nanopore assemblies including the alpha-hemolysin variants, the assembly having an increased nanopore lifetime. Further, provided are variants that, in addition to providing increased lifetime, provide a decreased time-to-thread. Hence, the variants provided herein both increase nanopore lifetime and improve efficiency and accuracy of DNA sequencing reactions using nanopores comprising the variants.

公开(公告)号：US12152068B2

公开(公告)日：2024-11-26

申请号：US17569377

申请日：2022-01-05

Applicant: TRELLIS BIOSCIENCE, LLC

Inventor： Lawrence M. Kauvar ,  Stefan Ryser ,  Angeles Estelles ,  Reyna J. Simon ,  Lauren Opremcak Bakaletz ,  Steven David Goodman

IPC: C07K16/12 ,  A61K35/12 ,  A61K39/00 ,  A61K39/40 ,  A61K45/06 ,  A61K49/00 ,  C07K14/31 ,  C12N15/86 ,  C12Q1/18 ,  G01N33/566 ,  G01N33/569

Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies secreted by human B lymphocytes. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.

公开(公告)号：US12134633B2

公开(公告)日：2024-11-05

申请号：US18298857

申请日：2023-04-11

Applicant: Cytiva BioProcess R&D AB

Inventor： Gustav José Rodrigo ,  Tomas Bjorkman ,  Mats Ander ,  Jesper Ulf Hansson

IPC: C07K1/22 ,  B01D15/38 ,  B01J20/24 ,  B01J20/28 ,  B01J20/286 ,  B01J20/32 ,  C07K14/31 ,  C07K16/00 ,  C07K16/06 ,  C07K17/10

Abstract: The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein: a) the ligands comprise multimers of alkali-stabilized Protein A domains, and b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.

公开(公告)号：US20240317837A1

公开(公告)日：2024-09-26

申请号：US18546061

申请日：2022-02-18

Applicant: ISOLERE BIO, INC.

Inventor： Kelli M. LUGINBUHL ,  Michael DZURICKY

IPC: C07K14/78 ,  C07K14/005 ,  C07K14/31 ,  C12N9/12 ,  C12P21/02

CPC classification number: C07K14/78 ,  C07K14/005 ,  C07K14/31 ,  C12N9/1247 ,  C12P21/02 ,  C07K2319/35 ,  C07K2319/50 ,  C12N2750/14122 ,  C12N2770/20022

Abstract: Provided herein are fusion proteins comprising a first polypeptide and a second polypeptide, wherein the second polypeptide has phase behavior. The first polypeptide may be a polypeptide having a desirable biological activity, such as a polypeptide with therapeutic, cosmetic, and/or industrial importance. Fusing the first polypeptide to the polypeptide with phase behavior facilitates purification thereof, and may also help to stabilize the first polypeptide during expression, storage, or after exposure to various conditions known to unfold, degrade, or misfold proteins.

公开(公告)号：US20240240246A1

公开(公告)日：2024-07-18

申请号：US18510933

申请日：2023-11-16

Applicant: Oxford Nanopore Technologies PLC

Inventor： Lakmal Jayasinghe ,  John Hagan Pryce Bayley ,  Stephen Cheley ,  Brian McKeown ,  James White ,  James Anthony Clarke

IPC: C12Q1/6869 ,  C07K14/31 ,  C12N9/12 ,  C12N9/16 ,  C12N9/22 ,  C12N9/52 ,  C12N9/90 ,  C12N9/96

CPC classification number: C12Q1/6869 ,  C07K14/31 ,  C12N9/1247 ,  C12N9/1252 ,  C12N9/127 ,  C12N9/1276 ,  C12N9/16 ,  C12N9/22 ,  C12N9/52 ,  C12N9/90 ,  C12N9/96

Abstract: The invention relates to constructs comprising a transmembrane protein pore subunit and a nucleic acid handling enzyme. The pore subunit is covalently attached to the enzyme such that both the subunit and enzyme retain their activity. The constructs can be used to generate transmembrane protein pores having a nucleic acid handling enzyme attached thereto. Such pores are particularly useful for sequencing nucleic acids. The enzyme handles the nucleic acid in such a way that the pore can detect its component nucleotides by stochastic sensing.

公开(公告)号：US20240174720A1

公开(公告)日：2024-05-30

申请号：US18356944

申请日：2023-07-21

Applicant: Bioprocessia Technologies LLC

Inventor： Yinong Zong

IPC: C07K14/31 ,  B01D15/38

CPC classification number: C07K14/31 ,  B01D15/3809

Abstract: This disclosure relates to chromatography ligands comprising one or more domains of Staphylococcal Protein A (SPA), or any functional variants thereof, as well as methods of making and using the same.

公开(公告)号：US20240100156A1

公开(公告)日：2024-03-28

申请号：US18166938

申请日：2023-02-09

Applicant: NeoTX Therapeutics Ltd.

Inventor： Asher Nathan ,  Michal Shahar

IPC: A61K39/395 ,  A61K38/16 ,  A61K39/00 ,  A61K39/085 ,  A61K47/68 ,  C07K14/31 ,  C07K16/28 ,  C07K16/30

CPC classification number: A61K39/39558 ,  A61K38/164 ,  A61K39/0011 ,  A61K39/085 ,  A61K39/39541 ,  A61K39/3955 ,  A61K47/6829 ,  A61K47/6851 ,  C07K14/31 ,  C07K16/2818 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/3053 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/585 ,  A61K2039/6056 ,  A61K2039/86 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/40 ,  C07K2319/55 ,  C07K2319/74

Abstract: The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with a PD-1 inhibitor.

公开(公告)号：US20240034750A1

公开(公告)日：2024-02-01

申请号：US18217257

申请日：2023-06-30

Applicant: Bioprocessia Technologies LLC

Inventor： Yinong Zong

IPC: C07K1/22 ,  B01D15/38 ,  B01J20/289 ,  B01J20/32 ,  C07K14/31 ,  C07K14/315 ,  C07K16/06

CPC classification number: C07K1/22 ,  B01D15/3804 ,  B01J20/289 ,  B01J20/3219 ,  B01J20/3274 ,  C07K14/31 ,  C07K14/315 ,  C07K16/065 ,  B01J2220/52 ,  C07K2319/21 ,  C07K2319/30

Abstract: The disclosure relates to chromatography ligands, e.g., chromatography ligands comprising at least two binding units and at least one spacer domain, wherein each binding unit comprises one or two immunoglobulin binding domains.

公开(公告)号：US20240018184A1

公开(公告)日：2024-01-18

申请号：US18354413

申请日：2023-07-18

Applicant: CYTIVA BIOPROCESS R&D AB

Inventor： Annika Forss ,  Gustav José Rodrigo ,  Tomas Bjorkman ,  Mats Ander ,  Jesper Ulf Hansson

IPC: C07K1/22 ,  B01J20/26 ,  B01J20/285 ,  B01J20/286 ,  B01J20/32 ,  C07K14/31 ,  C07K16/00 ,  C07K16/12 ,  C07K17/10

CPC classification number: C07K1/22 ,  B01J20/267 ,  B01J20/285 ,  B01J20/286 ,  B01J2220/52 ,  C07K14/31 ,  C07K16/00 ,  C07K16/1271 ,  C07K17/10 ,  B01J20/3274

Abstract: The present invention concerns a method of cleaning and/or sanitizing a separation matrix comprising multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support. The method comprises the steps of:

a) optionally purifying a mixture comprising a first immunoglobulin using the separation matrix;
b) providing a cleaning liquid comprising at least 50% by volume of an aqueous alkali metal hydroxide solution; and
c) cleaning and/or sanitizing the separation matrix by contacting the cleaning liquid with the separation matrix for a predetermined contact time.


The alkali-stabilized Protein A domains comprise mutants of a parental Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO 51 or SEQ ID NO 52, wherein the amino acid residues at positions 13 and 44 of SEQ ID NO 51 or 52 are asparagines and wherein at least the asparagine residue at position 3 of SEQ ID NO 51 or 52 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.